Table 2.

Psychopathology and clinical improvement measures at baseline, week 4 (end of Phase I) and week 8 (end of Phase II).

Measure, mean (SD)		Total sample N = 63	Fast responders *N = 37	Slow responders *N = 26
BPRS total	Baseline	54.8 (9.2)	55.1 (9.5)	54.4 (8.9)
	Week 4	41.4 (9.8)a	35.9 (5.0)a	49.2 (9.6)a
	Week 8†	39.1 (9.3)b,c	35.7 (6.9)c	43.9 (10.3)b,c
BPRS psychotic subscale	Baseline	14.6 (2.9)	14.3 (2.9)	15.0 (2.8)
	Week 4	9.9 (4.0)a	7.3 (1.4)a	13.7 (3.4)
	Week 8†	8.6 (3.5)b,c	7.4 (2.6)c	10.4 (3.9)b,c
BPRS negative symptoms subscale	Baseline	6.3 (2.2)	6.1 (2.2)	6.6 (2.1)
	Week 4	5.7 (1.7)a	5.3 (1.4)	6.2 (2.0)
	Week 8†	5.7 (1.7)c	5.1 (1.2)c	6.5 (1.9)
CGI-S	Baseline	4.5 (0.7)	4.5 (0.8)	4.5 (0.7)
	Week 4	3.2 (1.1)a	2.5 (0.6)a	4.2 (0.8)a
	Week 8†	2.8 (1.1)b,c	2.5 (1.0)c	3.3 (1.1)b,c
QLS	Baseline	58.8 (20.1)	57.9 (20.9)	60.0 (19.3)
	Week 4	68.3 (19.1)a	75.1 (18.0)a	58.5 (16.3)
	Week 8†	67.9 (20.8)c	74.8 (20.0)c	58.1 (18.1)

*Responder status determined after 4 weeks of risperidone at a dose of 2 mg/day.

^†Week 8 scores are on an LOCF basis for all measures.

^aSignificant change from baseline to week 4, P ≤ .05.

^bSignificant change from week 4 to week 8, P ≤ .05.

^cSignificant change from baseline to week 8, P ≤ .05.

BPRS: the Brief Psychiatric Rating Scale, CGI-S: Clinical Global Impression Severity Scale, QLS: Quality of Life Scale.